E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

被引：0
|
作者：
Hochster, Howard S.
Catalano, Paul J.
Mitchell, Edith P.
Cohen, Deirdre Jill
O'Dwyer, Peter J.
Benson, Al Bowen
机构：
[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] NYU, Inst Canc, New York, NY USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3665
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [32] Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan plus Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
    Sobrero, Alberto
    Lenz, Heinz-Josef
    Eng, Cathy
    Scheithauer, Werner
    Middleton, Gary
    Chen, Wenfeng
    Esser, Regina
    Nippgen, Johannes
    Burris, Howard
    ONCOLOGIST, 2021, 26 (02): : E261 - E269
  • [33] Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.
    Komatsu, Yoshito
    Yuki, Satoshi
    Nakatsumi, Hiroshi
    Hosokawa, Ayumu
    Nakamura, Michio
    Muto, Osamu
    Meguro, Takashi
    Iwanaga, Ichiro
    Hatanaka, Kazuteru
    Tsuji, Yasushi
    Sato, Atsushi
    Eto, Kazunori
    Furukawa, Kouichi
    Onodera, Manabu
    Tateyama, Miki
    Takahashi, Yasuo
    Dazai, Masayoshi
    Yokoyama, Sachio
    Honda, Takuya
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [35] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
  • [36] A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Townsend, A.
    Tebbutt, N.
    Karapetis, C.
    Cooper, P.
    Singhal, N.
    Yeend, S.
    Pirc, L.
    Joshi, R.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [38] A MULTICENTER PHASE2 STUDY OF SECOND-LINE FOLFIRI PLUS CETUXIMAB WITH KRAS WILD TYPE GENE IN METASTATIC CRC PATIENTS
    Goda, Fuminori
    Iwatamoto, Shigeyoshi
    Kato, Takeshi
    Matsuda, Chu
    Amagai, Kenji
    Inagaki, Hitoshi
    Bando, Hiroyuki
    Fukunaga, Mutsumi
    Okuyama, Yusuke
    Kobayashi, Kenji
    Hinoda, Yuji
    Sakamoto, Junnichi
    Hazama, Shoichi
    Mishima, Hideyuki
    ANNALS OF ONCOLOGY, 2010, 21 : 33 - 33
  • [39] RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer RESPONSE
    Sclafani, Francesco
    Cunningham, David
    Peckitt, Clare
    Watkins, David
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03):
  • [40] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
12345